A tablet you swallow with your morning coffee, or a shot once a week. That's the headline difference here — and it's a big one for a lot of people. But there's more going on underneath, including the odd fact that one of these isn't actually a peptide at all.
What's the actual difference?
Semaglutide is a peptide — a short chain of amino acids, the tiny building blocks that make up protein. Your body would normally digest something like that, which is why the famous versions (Ozempic, Wegovy) are injected.
Orforglipron is different. It's a small molecule — a compact lab-built chemical, closer in nature to a normal pill like ibuprofen than to Ozempic. That's the whole trick. Because it isn't a peptide, your stomach doesn't destroy it, so it works as a tablet.
Both aim at the same target: GLP-1, a gut hormone that tells your brain you've had enough to eat. Same destination, completely different vehicle.
The head-to-head
| Factor | Orforglipron | Semaglutide |
|---|---|---|
| What it is | An oral small molecule — not a peptide | A peptide (a short chain of amino acids) |
| Approved? | Yes — FDA-approved 1 April 2026 as Foundayo, for weight management | Yes — FDA-approved (Wegovy for weight, Ozempic for type 2 diabetes) |
| How it's taken | A tablet, once a day | Usually a weekly injection; an oral version also exists |
| What trials showed | Phase 3 trials (ATTAIN-1, ATTAIN-2) showed meaningful weight loss versus placebo | Phase 3 STEP 1 showed about 14.9% average body-weight loss over 68 weeks versus about 2.4% on placebo |
| Main side effects | Mostly gut-related — nausea, vomiting, diarrhoea; carries a boxed warning | Mostly gut-related — nausea, vomiting, diarrhoea; carries a boxed warning |
| Banned in sport? | Not a WADA-prohibited substance, but check current rules with your governing body | Not a WADA-prohibited substance, but check current rules with your governing body |
Which one works better?
Honest answer: nobody has run the clean head-to-head trial against injected semaglutide yet, so anyone giving you a confident winner is guessing.
What we do have is a comparison between the two oral options. A 2026 analysis (funded by Novo Nordisk, semaglutide's maker — worth knowing) lined up trial data for oral semaglutide against orforglipron indirectly, and oral semaglutide came out ahead on weight loss, with fewer people quitting because of side effects. That's a sponsored indirect comparison, not a head-to-head trial, so treat it as a hint rather than a verdict.
The fairer summary: semaglutide has years more real-world use and a much deeper evidence pile. Orforglipron is brand new and its selling point is the format, not a proven efficacy advantage.
Which is safer?
They land in a similar place. Both mainly cause gut trouble — nausea, vomiting, diarrhoea — especially early on. Both carry a boxed warning, which is the strongest warning the FDA puts on a label. Neither is a soft option just because one comes as a tablet.
One quirk worth mentioning: in a 2026 meta-analysis pooling GLP-1 trials, all of these drugs nudged resting heart rate upward, and orforglipron showed the largest increase. That's one signal in one pooled analysis, not a scare story, but it's the kind of thing a doctor factors in and a website can't.
What's true
- Both are FDA-approved, prescription-only medicines for weight management
- Orforglipron is a tablet; semaglutide's best-known versions are injections
- Orforglipron is a small molecule, not a peptide — that's why it survives your stomach
- Semaglutide has substantially more long-term human evidence behind it
What's a myth
- 'A pill means milder side effects' — the gut side effects and the boxed warning are still there
- 'Orforglipron beats semaglutide' — no head-to-head trial has shown that
- 'It's new, so it must be better' — new means less long-term data, not more
Which should you ask a doctor about?
If needles are the thing stopping you, orforglipron is the obvious conversation to have — a daily tablet removes a real barrier. If you want the option with the longest track record and the biggest evidence base, that's semaglutide. Cost, insurance coverage, and what's actually stocked where you live will probably decide it anyway, and a pharmacist can tell you that faster than the internet can.
The honest verdict
This isn't a good-versus-bad comparison. Both are legitimate approved medicines that hit the same appetite switch. Orforglipron wins on convenience. Semaglutide wins on depth of evidence. Nobody has proven either one is more effective than the other in a direct trial, so let a doctor weigh your history rather than picking a side based on a headline.
What this does not mean
- This doesn't mean a pill is gentler than an injection — the side-effect profiles are broadly similar and both carry a boxed warning.
- This doesn't mean orforglipron is proven better or worse than injected semaglutide — that head-to-head trial hasn't been published.
- This doesn't mean either drug is right for you — approval means a regulator cleared it for specific patients, not for everyone.
- This is general information, not medical advice. A doctor decides which medicine, if any, fits your situation.